Privium Fund Management B.V. Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Privium Fund Management B.V. grew its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 103.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,476 shares of the company's stock after buying an additional 41,994 shares during the period. Moderna accounts for 0.8% of Privium Fund Management B.V.'s investment portfolio, making the stock its 23rd largest position. Privium Fund Management B.V.'s holdings in Moderna were worth $3,429,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB raised its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new position in Moderna in the fourth quarter worth about $37,000. Venturi Wealth Management LLC boosted its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after acquiring an additional 389 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares during the period. Institutional investors own 75.33% of the company's stock.

Remove Ads

Moderna Trading Up 0.6 %

Shares of MRNA stock traded up $0.21 during mid-day trading on Friday, reaching $32.66. The stock had a trading volume of 9,318,798 shares, compared to its average volume of 6,630,174. The business has a 50-day simple moving average of $34.91 and a 200 day simple moving average of $45.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The company has a market cap of $12.60 billion, a P/E ratio of -3.52 and a beta of 1.86.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MRNA shares. Morgan Stanley dropped their price target on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 15th. Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Evercore ISI set a $50.00 price target on Moderna in a research report on Friday, February 14th. Finally, Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.